Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Mexico
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Gilead Sciences Inc

+ Add to Watchlist

GILD*:MM

1,570.45 MXN 11.25 0.71%

As of 16:09:35 ET on 05/06/2015.

Snapshot for Gilead Sciences Inc (GILD*)

Open: 1,580.00 Day's Range: 1,555.00 - 1,580.00 Volume: 16,044
Previous Close: 1,581.70 52wk Range: 1,000.00 - 1,700.00 1-Yr Rtn: +53.43%

Stock Chart for GILD*

No chart data available.
  • GILD*:MM 1,570.45
  • 1D
  • 1M
  • 1Y
1,581.70
Interactive GILD* Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GILD*

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 9.9574
Relative P/E vs. MEXBOL -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 10.2830
Est. PEG Ratio 0.8101
Market Cap (M MXN) 2,329,075.75
Shares Outstanding (M) 1,483.06
30 Day Average Volume 15,935
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.68%
Cash Dividend (USD) 0.4300
Dividend Ex-Date 06/12/2015
5 Year Dividend Growth -
Next Earnings Announcement 07/23/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GILD*

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for GILD*

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

John C MartinChairman/CEOJohn F MilliganPresident/COO
Robin L WashingtonExec VP/CFOPaul R CarterExec VP:Commercial Operations
More Company Profile & Key Executives for GILD*

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil